



NitricGen Inc.

NitricGen Inc. Receives a Small Business Innovation Research (SBIR) Grant for Treating Chronic Diabetic Foot Ulcers.

Madison, WI, September 23, 2013- NitricGen, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant in the amount of \$259,536 by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH). The title of the project is “Healing of Diabetic Ulcers with Gaseous Nitric Oxide Generated From Room Air”. This research project is designed to achieve two key aims: to produce a novel research device that produces Nitric Oxide from room air; and to test its effect on wound healing in a diabetic mouse model. NitricGen is collaborating with Aristidis Veves MD, Research Director, Joslin –Beth Israel Deaconess Foot Center, and Professor of Surgery, Harvard Medical School, for the conduct of the animal research studies. Dr. Veves is a well-known researcher in the field of diabetic foot ulcer research, in both animal and human studies. Nitric Oxide is a natural gas molecule that is essential in controlling many biological functions, including wound healing. This research will be the first to investigate the effect of Nitric Oxide in an animal diabetic wound model.

NitricGen would like to thank Cheryl Vickroy, Director of Wisconsin Entrepreneurs’ Network, and Kafryn W. Lieder, PhD, from The Well-Tempered Word, LLC, for providing support and guidance with the grant submission.

About NitricGen:

NitricGen, Inc. is an early phase Medical Device Company based in Madison, WI. The Company has designed a novel compact medical device “The eNO Generator” for producing gaseous nitric oxide to treat chronic diabetic foot ulcers. Nitric Oxide is a small regulatory molecule, which is naturally produced by the human body. Research over the last twenty years has shown it to be essential for controlling numerous biological functions including the successful healing of chronic wounds. The early researchers who discovered the role of nitric oxide in the human body went on to win the Noble Prize for Medicine in 1998. Patients with chronic diabetic foot ulcers face a debilitating condition with poor quality of life, open wounds that fail to heal, limited mobility with close to a million patients in the US, and over 80,000 patients a year ultimately requiring amputations. There is a clear need for new more effective treatment, such as nitric oxide therapy, for healing these chronic diabetic foot ulcers.

For additional information, please email info@nitricgen.com